Literature DB >> 22856670

Chemotherapy-related changes in central nervous system phospholipids and neurocognitive function in childhood acute lymphoblastic leukemia.

Kevin R Krull1, Marilyn J Hockenberry, Petra Miketova, Marissa Carey, Ida M Moore.   

Abstract

Long-term survivors of childhood leukemia are at risk for neurocognitive impairment, although the neurophysiological basis is not well understood. The purpose of this study was to explore associations between changes in cerebrospinal fluid (CSF) phospholipids and neurocognitive function in children undergoing chemotherapy for acute lymphoblastic leukemia. Seventy-six children were followed prospectively from diagnosis. CSF samples were collected during scheduled lumbar punctures and phospholipids were extracted. Neurocognitive evaluations were conducted annually beginning shortly after diagnosis. Concentrations of sphingomyelin (SM) increased following induction (p = 0.03) and consolidation (p = 0.04), while lysophosphatidylcholine (LPC) increased following induction (p = 0.003). Multivariable analyses demonstrated associations between post-induction SM and motor speed at 1 year (p < 0.001), 2 years (p = 0.001) and 3 years (p = 0.02) following diagnosis. Post-induction LPC was associated with verbal working memory (p = 0.007). Results indicate that early changes in phospholipids are related to neurocognitive decline and suggest a chemotherapy impact on white matter integrity.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22856670      PMCID: PMC3845091          DOI: 10.3109/10428194.2012.717080

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN: 1026-8022


  30 in total

1.  Neuropsychological, neuroanatomical, and neurophysiological consequences of CNS chemotherapy for acute lymphoblastic leukemia.

Authors:  M Moleski
Journal:  Arch Clin Neuropsychol       Date:  2000-10       Impact factor: 2.813

Review 2.  Prevalence of leukoencephalopathy in children treated for acute lymphoblastic leukemia with high-dose methotrexate.

Authors:  Wilburn E Reddick; John O Glass; Kathleen J Helton; James W Langston; Xiaoping Xiong; Shengjie Wu; Ching-Hon Pui
Journal:  AJNR Am J Neuroradiol       Date:  2005-05       Impact factor: 3.825

3.  Lysophosphatidylcholine as a ligand for immunoregulation.

Authors:  Janusz H S Kabarowski; Yan Xu; Owen N Witte
Journal:  Biochem Pharmacol       Date:  2002-07-15       Impact factor: 5.858

4.  Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia and its relationship to other prognostic factors: a Children's Oncology Group study.

Authors:  Michael J Borowitz; Meenakshi Devidas; Stephen P Hunger; W Paul Bowman; Andrew J Carroll; William L Carroll; Stephen Linda; Paul L Martin; D Jeanette Pullen; David Viswanatha; Cheryl L Willman; Naomi Winick; Bruce M Camitta
Journal:  Blood       Date:  2008-04-03       Impact factor: 22.113

5.  Neurobehavioural sequelae following cranial irradiation and chemotherapy in children: an analysis of risk factors.

Authors:  V Anderson; T Godber; E Smibert; H Ekert
Journal:  Pediatr Rehabil       Date:  1997 Apr-Jun

6.  Decreased lysophosphatidylcholine/phosphatidylcholine ratio in cerebrospinal fluid in Alzheimer's disease.

Authors:  C Mulder; L-O Wahlund; T Teerlink; M Blomberg; R Veerhuis; G J van Kamp; P Scheltens; P G Scheffer
Journal:  J Neural Transm (Vienna)       Date:  2003-08       Impact factor: 3.575

7.  Lysophosphatidylcholine induces delayed myelination in the juvenile ventral hippocampus and behavioral alterations in adulthood.

Authors:  Manabu Makinodan; Kouko Tatsumi; Hiroaki Okuda; Takayuki Manabe; Takahira Yamauchi; Yoshinobu Noriyama; Toshifumi Kishimoto; Akio Wanaka
Journal:  Neurochem Int       Date:  2008-09-21       Impact factor: 3.921

8.  Therapeutic effects of lysophosphatidylcholine in experimental sepsis.

Authors:  Ji-Jing Yan; Jun-Sub Jung; Jung-Eun Lee; Jongho Lee; Sung-Oh Huh; Hee-Sung Kim; Kyeong Cheon Jung; Jae-Young Cho; Ju-Suk Nam; Hong-Won Suh; Yung-Hi Kim; Dong-Keun Song
Journal:  Nat Med       Date:  2004-01-11       Impact factor: 53.440

9.  Antimetabolite therapy for lesser-risk B-lineage acute lymphoblastic leukemia of childhood: a report from Children's Oncology Group Study P9201.

Authors:  Allen R Chauvenet; Paul L Martin; Meenakshi Devidas; Stephen B Linda; Beverly A Bell; Joanne Kurtzberg; Jeanette Pullen; Mark J Pettenati; Andrew J Carroll; Jonathan J Shuster; Bruce Camitta
Journal:  Blood       Date:  2007-04-18       Impact factor: 22.113

Review 10.  Identification of disease markers in human cerebrospinal fluid using lipidomic and proteomic methods.

Authors:  Alfred N Fonteh; Robert J Harrington; Andreas F Huhmer; Roger G Biringer; James N Riggins; Michael G Harrington
Journal:  Dis Markers       Date:  2006       Impact factor: 3.434

View more
  15 in total

Review 1.  Neurodevelopmental consequences of pediatric cancer and its treatment: applying an early adversity framework to understanding cognitive, behavioral, and emotional outcomes.

Authors:  Hilary A Marusak; Allesandra S Iadipaolo; Felicity W Harper; Farrah Elrahal; Jeffrey W Taub; Elimelech Goldberg; Christine A Rabinak
Journal:  Neuropsychol Rev       Date:  2017-12-22       Impact factor: 7.444

2.  The association of age, literacy, and race on completing patient-reported outcome measures in pediatric oncology.

Authors:  Janice S Withycombe; Molly McFatrich; Laura Pinheiro; Pamela S Hinds; Frank G Keller; Justin N Baker; Jenny W Mack; Lillian Sung; Mia K Waldron; Bryce B Reeve
Journal:  Qual Life Res       Date:  2019-01-17       Impact factor: 4.147

Review 3.  Neurocognitive Outcomes and Interventions in Long-Term Survivors of Childhood Cancer.

Authors:  Kevin R Krull; Kristina K Hardy; Lisa S Kahalley; Ilse Schuitema; Shelli R Kesler
Journal:  J Clin Oncol       Date:  2018-06-06       Impact factor: 44.544

4.  Atypical Structural Connectome Organization and Cognitive Impairment in Young Survivors of Acute Lymphoblastic Leukemia.

Authors:  Shelli R Kesler; Meike Gugel; Emily Huston-Warren; Christa Watson
Journal:  Brain Connect       Date:  2016-03-29

5.  Neurocognitive Predictors of Academic Outcomes Among Childhood Leukemia Survivors.

Authors:  Ida M Ki Moore; Philip J Lupo; Kathleen Insel; Lynnette L Harris; Alice Pasvogel; Kari M Koerner; Kristin B Adkins; Olga A Taylor; Marilyn J Hockenberry
Journal:  Cancer Nurs       Date:  2016 Jul-Aug       Impact factor: 2.592

6.  Feasibility of baseline neurocognitive assessment using Cogstate during the first month of therapy for childhood leukemia.

Authors:  Stephen A Sands; Brian T Harel; Mirko Savone; Kara Kelly; Veena Vijayanathan; Jennifer Greene Welch; Lynda Vrooman; Lewis B Silverman; Peter D Cole
Journal:  Support Care Cancer       Date:  2016-10-10       Impact factor: 3.603

7.  Evolution of neurocognitive function in long-term survivors of childhood acute lymphoblastic leukemia treated with chemotherapy only.

Authors:  Wei Liu; Yin Ting Cheung; Heather M Conklin; Lisa M Jacola; DeoKumar Srivastava; Vikki G Nolan; Hongmei Zhang; James G Gurney; I-Chan Huang; Leslie L Robison; Ching-Hon Pui; Melissa M Hudson; Kevin R Krull
Journal:  J Cancer Surviv       Date:  2018-02-27       Impact factor: 4.442

8.  Brain size and neuropsychological functioning in long-term survivors of pediatric acute lymphoblastic leukemia.

Authors:  Jean M Mulcahy Levy; Stephen P Hunger
Journal:  Transl Pediatr       Date:  2013-10

9.  Increase in oxidative stress as measured by cerebrospinal fluid lipid peroxidation during treatment for childhood acute lymphoblastic leukemia.

Authors:  Ida M Ki Moore; Patricia Gundy; Alice Pasvogel; David W Montgomery; Olga A Taylor; Kari M Koerner; Kathy McCarthy; Marilyn J Hockenberry
Journal:  J Pediatr Hematol Oncol       Date:  2015-03       Impact factor: 1.289

10.  Longitudinal Trajectories of Neurocognitive Functioning in Childhood Acute Lymphoblastic Leukemia.

Authors:  Marita Partanen; Sean Phipps; Kathryn Russell; Doralina L Anghelescu; Joshua Wolf; Heather M Conklin; Kevin R Krull; Hiroto Inaba; Ching-Hon Pui; Lisa M Jacola
Journal:  J Pediatr Psychol       Date:  2021-02-19
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.